Stocks › ATOS
ATOSSA THERAPEUTICS, INC.
ATOS·Nasdaq·
United States·USD
United States·USD$2.46
+0.01 (+0.41%)
Close · Oct 7, 2026 · Close Prices from Tiingo.com
ATOS
ATOSSA THERAPEUTICS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ATOSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ATOS by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Roger MarshallHouse · R · KS |
ATOSATOSSA THERAPEUTICS, INC. · Stock |
Purchase $1,001 - $15,000 |
Aug 6, 2018 | Oct 25, 2017 | Filing ↗ |
Whale Activity
Position changes in ATOS reported for 2026-06-30 by 4 tracked institutional filers
- Increased3
- New0
- Held0
- Decreased1
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 361.7K | $698K | increased |
| BlackRock, Inc. | 164.4K | $317K | increased |
| RENAISSANCE TECHNOLOGIES LLC | 132.0K | $255K | increased |
| MILLENNIUM MANAGEMENT LLC | 46.5K | $90K | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ATOS insiders, by quarter · Form 4
Recent Insider Transactions
49 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Steinhart Richard IDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| Chen Shu-ChihDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| Remmel H. LawrenceDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| Finn JonathanDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| Galli Stephen JDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| Cigler TessaDirector | Grant / award | +10.0K | $0.00 | $0 | May 12, 2026 | Form 4 ↗ |
| QUAY STEVEN CPresident & CEO · Director | Grant / award | +65.0K | $0.00 | $0 | Mar 27, 2026 | Form 4 ↗ |
| Daniel Mark JamesChief Financial Officer | Grant / award | +63.0K | $0.00 | $0 | Mar 26, 2026 | Form 4 ↗ |
| QUAY STEVEN CPresident & CEO · Director | Grant / award Amended | +331.7K | $0.00 | $0 | Jan 20, 2026 | Form 4 ↗ |
| QUAY STEVEN CPresident & CEO · Director | Grant / award | +325.2K | $0.00 | $0 | Jan 20, 2026 | Form 4 ↗ |
| QUAY STEVEN CPresident & CEO · Director | Purchase | +11.2K | $0.88 | $10K | May 21, 2025 | Form 4 ↗ |
| Remmel H. LawrenceDirector | Purchase | +10.0K | $0.70 | $7K | Mar 26, 2025 | Form 4 ↗ |
| Finn JonathanDirector | Purchase | +25.0K | $1.77 | $44K | Apr 10, 2024 | Form 4 ↗ |
| WEAVER GREGORY LFormer EVP, CFO, & Director · Director | Sale | −50.0K | $0.65 | $33K | Nov 15, 2023 | Form 4 ↗ |
| WEAVER GREGORY LEVP & CFO · Director | Purchase | +50.0K | $0.97 | $49K | Jun 20, 2023 | Form 4 ↗ |
| WEAVER GREGORY LDirector | Sale | −107.5K | $5.58 | $600K | Jul 2, 2021 | Form 4 ↗ |
| WEAVER GREGORY LDirector | Tax withholding | −57.1K | $6.40 | $365K | Jul 2, 2021 | Form 4 ↗ |
| WEAVER GREGORY LDirector | Option exercise | +70.0K | $1.70 | $119K | Jul 2, 2021 | Form 4 ↗ |
| WEAVER GREGORY LDirector | Option exercise | +45.0K | $2.52 | $113K | Jul 2, 2021 | Form 4 ↗ |
| WEAVER GREGORY LDirector | Option exercise | +45.0K | $2.38 | $107K | Jul 2, 2021 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ATOS · SEC Form N-PORT
No mutual fund or ETF has reported ATOS in an N-PORT filing in the last seven months.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming atossa therapeutics as client
No lobbying filings found naming ATOSSA THERAPEUTICS, INC. as the client.
- DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2021 Q1 · MED$40K
Filing ↗ - DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q4 · MED$40K
Filing ↗ - DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q3 · MED$40K
Filing ↗ - DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q2 · MED$20K
Filing ↗ - DESIMONE CONSULTING, LLCATOSSA THERAPEUTICS, INC. · 2020 Q2 · MED—
Filing ↗
Government Contracts
Federal awards to ATOSSA THERAPEUTICS, INC. · USAspending
No federal contract awards found for ATOSSA THERAPEUTICS, INC..
U.S. Patents
Recent USPTO applications naming ATOSSA THERAPEUTICS, INC.
No USPTO patent applications found for ATOSSA THERAPEUTICS, INC..
Annual Financials
From ATOS's 10-K filings · XBRL
No annual XBRL figures on record for ATOS. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-15Reverse splitFeb 2, 2026
- 1-for-12Reverse splitApr 20, 2018
- 1-for-15Reverse splitAug 26, 2016
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 8.01, 9.01Other eventsSep 29, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureSep 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 7, 2026
EDGAR ↗ - 8-K · Items 1.01, 9.01Material agreementJun 11, 2026
EDGAR ↗ - 8-K · Items 9.01May 8, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 8, 2026
EDGAR ↗
About ATOSSA THERAPEUTICS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSEATTLE, WA
IncorporatedDE
SEC CIK0001488039 ↗
Former namesATOSSA GENETICS INC